Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1421650 | 0.82 | GRM5 (0.47) | GRM5 | |
| SCHEMBL3182180 | 0.82 | TTR (0.40) | EGLN2 | |
| SCHEMBL2011602 | 0.82 | TTR (0.40) | EGLN2 | |
| SCHEMBL56741 | 0.82 | GRM5 (0.43) | GRM5 | |
| Hydrochloric Acid SCHEMBL9495207 | 0.79 | TTR (0.39) | EGLN2 | |
| SCHEMBL1639074 | 0.76 | CYP1A1 (0.31) | — | |
| SCHEMBL4452362 | 0.76 | GRM5 (0.42) | GRM5 | |
| SCHEMBL4457929 | 0.75 | GRM5 (0.56) | GRM5 | |
| SCHEMBL13606452 | 0.75 | GRM5 (0.53) | MAP4K4GRM5 | |
| SCHEMBL15650249 | 0.73 | MAP4K4 (0.40) | MAP4K4EGLN2GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 277 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150274661-A1 | INDOL-AMIDE COMPOUNDS AS BETA-AMYLOID INHBITORS | HOFFMANN-LA ROCHE INC. (US) | 2015-10-01 | — | — | US | claimed |
| EP-2909190-A1 | INDOL-AMIDE COMPOUNDS AS BETA-AMYLOID INHBITORS | F. Hoffmann-La Roche AG (CH) | 2015-08-26 | — | — | EP | claimed |
| WO-2014060386-A1 | INDOL-AMIDE COMPOUNDS AS BETA-AMYLOID INHBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-04-24 | — | — | WO | claimed |
| EP-2722329-A1 | Indol-amide compounds as beta-amyloid inhbitors | F. Hoffmann-La Roche AG (CH) | 2014-04-23 | — | — | EP | claimed |
| EP-1844044-B1 | THIAZOLE-4-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-07-21 | — | — | EP | claimed |
| US-20100166765-A1 | BENZOQUINAZOLINE DERIVATIVES | NOVARTIS AG (CH) | 2010-07-01 | — | — | US | claimed |
| US-7678815-B2 | Thiazole-4-carboxyamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-03-16 | — | — | US | claimed |
| EP-1917246-B1 | BENZOQUINAZOLINE DERIVATIVES AND THEIR USE IN TREATING BONE DISORDERS | NOVARTIS AG (CH) | 2009-11-11 | — | — | EP | claimed |
| EP-1917246-A1 | BENZOQUINAZOLINE DERIVATIVES AND THEIR USE IN TREATING BONE DISORDERS | Novartis AG (CH) | 2008-05-07 | — | — | EP | claimed |
| EP-1844044-A1 | THIAZOLE-4-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-10-17 | — | — | EP | claimed |
| WO-2007020046-A1 | BENZOQUINAZOLINE DERIVATIVES AND THEIR USE IN TREATING BONE DISORDERS | NOVARTIS AG (CH) | 2007-02-22 | — | — | WO | claimed |
| US-20060160857-A1 | Thiazole-4-carboxyamide derivatives | HOFFMANN-LA ROCHE INC. | 2006-07-20 | — | — | US | claimed |
| WO-2006074884-A1 | THIAZOLE-4-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-07-20 | — | — | WO | claimed |
| EP-3887359-B1 | NOVEL TETRAZINE COMPOUNDS FOR IN VIVO IMAGING | UNIV COPENHAGEN (DK) | 2026-05-06 | — | — | EP | disclosed |
| US-12528827-B2 | Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as PAR4 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-01-20 | — | — | US | disclosed |
| US-20250340508-A1 | TETRAHYDRO-1H-CYCLOPENTA[CD]INDENE DERIVATIVES AS HYPOXIA INDUCIBLE FACTOR-2(ALPHA) INHIBITORS | NIKANG THERAPEUTICS INC (US) | 2025-11-06 | — | — | US | disclosed |
| WO-2005066155-A1 | 5-FLUORO-, CHLORO- AND CYANO-PYRIDIN-2-YL-TETRAZOLES AS LIGANDS OF THE METABOTROPIC GLUTAMATE RECEPTOR-5 | ASTRAZENECA AB (SE) | 2005-07-21 | — | — | WO | disclosed |
| US-6552018-B1 | As antitumor agents | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-04-22 | — | — | US | disclosed |
| US-6169086-B1 | AN ANTITUMOR AGENT FOR TREATING TUMOR RESISTANT TO 5-FLUOROURACIL TYPE DRUGS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-01-02 | — | — | US | disclosed |
| EP-1022270-A1 | PYRAZOLE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2000-07-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160857-A1 | Thiazole-4-carboxyamide derivatives | GRM1, GRM2, GRIA4 | MAP4K4 2305/4885EGLN2 2442/4885GRM5 4/4885 |
| US-20250340508-A1 | TETRAHYDRO-1H-CYCLOPENTA[CD]INDENE DERIVATIVES AS HYPOXIA INDUCIBLE FACTOR-2(ALPHA) INHIBITORS | HIF1AN, HIF1A, HYOU1 | MAP4K4 3531/4885EGLN2 6/4885GRM5 3768/4885 |
| US-20100166765-A1 | BENZOQUINAZOLINE DERIVATIVES | CACNA1A, BMP4, TPX2 | MAP4K4 1232/4885EGLN2 211/4885GRM5 2344/4885 |
| US-12528827-B2 | Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as PAR4 inhibitors | F2RL3, F2R, PF4 | MAP4K4 1821/4885EGLN2 3047/4885GRM5 3238/4885 |
| US-20150274661-A1 | INDOL-AMIDE COMPOUNDS AS BETA-AMYLOID INHBITORS | APP, BACE1, IAPP | MAP4K4 3241/4885EGLN2 2607/4885GRM5 2894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.